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Background: We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in
pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC).
Methods: The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N¼ 241, study 1). Suggestive
associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib
(N¼ 729, study 2) and an observational study of sunitinib-treated patients (N¼ 89, study 3).
Results: In study 1, four SNPs showed nominally significant association (Pr0.05) with OS; two of these SNPs (rs1126647, rs4073) in
IL8 were associated (Pr0.05) with OS in study 2. Because rs1126647 and rs4073 were highly correlated, only rs1126647 was
evaluated in study 3, which also showed association (Pr0.05). In the combined data, rs1126647 was associated with OS after
conservative multiple-test adjustment (P¼ 8.8 10 5; variant vs reference allele hazard ratio 1.32, 95% confidence interval: 1.15–
1.52), without evidence for heterogeneity of effects between studies or between pazopanib- and sunitinib-treated patients.
Conclusions: Variant alleles of IL8 polymorphisms are associated with poorer survival outcomes in pazopanib- or sunitinib-treated
patients with aRCC. These findings provide insight in aRCC prognosis and may advance our thinking in development of new therapies.
Renal cell carcinoma (RCC) is a heterogeneous collection of
malignancies arising from the renal parenchyma, with 4200 000
new cases worldwide per year (Gupta et al, 2008; Escudier et al, 2013).
Although highly curable in its localised form by surgery,
approximately a third of patients are diagnosed when metastatic
spread has already occurred (Gupta et al, 2008); in addition,
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approximately 30% of patients surgically treated for a localised
primary tumour will eventually develop metastases over time
(Janowitz et al, 2013). The development of targeted systemic
treatment options has improved clinical outcomes in patients
with advanced and metastatic RCC (Molina and Motzer, 2011;
Escudier et al, 2013; Fisher et al, 2013). Initial treatment decisions
are based on prognosis of the disease using risk assessment
models. Such prognostic models, initially developed for stratifica-
tion of patients with metastatic RCC undergoing cytokine
treatment (Motzer et al, 1999), have recently been extended
to apply to patients receiving targeted therapies (Heng et al,
2009, 2013).
Pazopanib and sunitinib are angiogenesis inhibitors with
highest affinity for vascular endothelial growth factor receptors,
platelet-derived growth factor receptors, and stem cell factor
receptor c-Kit (Motzer et al, 2007; Sternberg et al, 2010), and are
approved for the treatment of advanced RCC. Treatment
guidelines (Motzer et al, 2014; Escudier et al, 2014b) include
both therapies as first-line options for RCC. Progression-free
survival (PFS) benefits were observed for both sunitinib (vs
interferon-alfa) and pazopanib (vs placebo) in their respective
pivotal phase III studies (Motzer et al, 2007; Sternberg et al,
2010), but overall survival (OS) benefits were either marginal or
not statistically significant (Motzer et al, 2007; Sternberg et al,
2013). However, these OS analyses were confounded by
crossover or access to other therapies after progression.
A recently completed phase III randomised clinical trial
(COMPARZ) comparing pazopanib vs sunitinib for RCC
demonstrated similar efficacies but differential safety profiles
for the two therapies (Motzer et al, 2013), and a randomised
cross-over phase III study (PISCES) demonstrated a significant
patient preference for pazopanib over sunitinib with health-
related quality of life and safety as key influencing factors
(Escudier et al, 2014a).
There is substantial heterogeneity between patients with
advanced RCC in prognosis and in response to treatment with
targeted therapies, including pazopanib and sunitinib, and
biomarkers that are predictive of clinical benefit would facilitate
evidence-based selection of particular agents or dosages for
optimal treatment of individual patients. The most obvious
candidate biomarkers in clear-cell metastatic RCC (e.g., von
Hippel–Lindau status, hypoxia-inducible factor (HIF) expres-
sion) have not been proven to have predictive significance
(Fisher et al, 2013). As noted in recent reviews (Funakoshi et al,
2014; Maroto and Rini, 2014), some retrospective and prospec-
tive studies have reported potential molecular prognostic or
predictive factors, including serum biomarkers (Tran et al, 2012;
Harmon et al, 2014), tumour biomarkers (Rini et al, 2010;
Dornbusch et al, 2013), and germline genetic variants (Garcia-
Donas et al, 2011; van der Veldt et al, 2011; Xu et al, 2011;
Scartozzi et al, 2013). Specifically, genetic polymorphisms in
genes involved in sunitinib pharmacokinetics (e.g., CYP3A5,
NR1I3, and ABCB1) or mode of action (e.g., VEGFR3) have
recently been reported to be associated with PFS or OS in
advanced RCC (Garcia-Donas et al, 2011; Scartozzi et al, 2013).
We have previously reported that genetic polymorphisms in IL8
and HIF1A may be associated with PFS, and polymorphisms in
HIF1A, NR1I2, and VEGFA may be associated with best response
(Xu et al, 2011). None of these genetic studies reported any
attempt to confirm the association(s) in an independent dataset.
To our knowledge, no prognostic or predictive biomarkers have
yet to be prospectively validated in multiple independent studies
to reliably distinguish patients with advanced RCC who are likely
to respond from those who will not. To identify genetic
predictors for OS, the present study used three independent
datasets totalling 1059 pazopanib- or sunitinib-treated patients
with advanced RCC.
MATERIALS AND METHODS
Patients. The discovery study (hereafter study 1) used data
from participants in trials NCT00334282/VEG105192 and
NCT00387764/VEG107769. The preplanned confirmation study
(hereafter study 2) used data from participants in the COMPARZ
trial: NCT00720941/VEG108844 and NCT01147822/VEG113078.
Studies 1 and 2 included patients who provided written informed
consent both for the clinical study and for genetic research. These
clinical studies were conducted in accordance with the Declaration
of Helsinki; protocols and informed consent forms were reviewed
and approved by Institutional Review Boards and Independent
Ethics Committees according to local guidelines. Post hoc,
additional confirmation was sought using an observational study
(hereafter study 3); the protocol was approved by the medical
ethics review board of each participating institution and each
participant provided written informed consent (Garcia-Donas
et al, 2011).
Patient characteristics have been described previously
(Sternberg et al, 2010; Garcia-Donas et al, 2011; Xu et al, 2011;
Motzer et al, 2013) (Table 1). Briefly, NCT00334282 was a
randomised, double-blind, placebo-controlled, pivotal phase III
pazopanib study for advanced and/or metastatic RCC (Sternberg
et al, 2010). NCT00387764 was an open-label extension to
NCT00334282 providing the option for placebo-treated patients
who developed progressive disease to receive pazopanib; OS for
these patients was calculated from the time of initiation of
pazopanib treatment in NCT00387764. Of the 369 patients
enrolled in NCT00334282 and NCT00387764 who received
pazopanib, study 1 used data from 241 patients who provided
consent and a blood sample for genetic research. COMPARZ was a
phase III randomised clinical trial comparing pazopanib vs
sunitinib for metastatic RCC (Motzer et al, 2013). Of 1110 patients
enrolled in COMPARZ, study 2 used data from 729 patients who
received either pazopanib (N¼ 374) or sunitinib (N¼ 355) and
provided consent and a blood sample for genetic research. Study 3
was an observational study undertaken by the Spanish Oncology
GenitoUrinary Group (SOGUG); sunitinib-treated patients with
clear-cell advanced RCC were included (N¼ 89). Compared with
the analysis reported previously by Garcia-Donas (27 patients died,
median follow-up 21.2 months) (Garcia-Donas et al, 2011), this
analysis uses data from extended follow-up for OS (50 patients
died, median follow-up 36.9 months).
Procedures. For studies 1 and 2, germline DNA was extracted
from peripheral blood (QiAamp DNA Blood Kit; Qiagen, Valencia,
CA, USA). In the discovery analysis, 27 potential functional single
nucleotide polymorphisms (SNPs) were selected from 13 candidate
genes with evidence of involvement in angiogenesis or in the
metabolism, disposition, or mode of action of pazopanib (Xu et al,
2011). Genotyping was conducted using single-base chain exten-
sion assays modified by GlaxoSmithKline (Research Triangle Park,
NC, USA), TaqMan SNP assays (Applied Biosystems, Foster City,
CA, USA), GoldenGate and Infinium genotyping assays (Illumina,
San Diego, CA, USA), the KASPar SNP genotyping system
(LGC Genomics, Hoddesdon, UK), and Sanger sequencing.
For study 3, DNA was isolated from peripheral blood with
FlexiGene DNA kit (Qiagen) or from saliva with Oragene DNA
self-collection kits (DNA Genotek, Ottawa, Canada), and geno-
typing was conducted using the KASPar SNP genotyping system
(Garcia-Donas et al, 2011).
All genotypes were called following the assay manufacturers’
guidelines. Genotyping quality was confirmed by call rate, manual
examination of cluster plots, concordance with previously reported
allele frequencies, and checks of Hardy–Weinberg proportions
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within self-reported non-Hispanic white patients and within self-
reported East Asian patients.
Statistical analysis. In study 1 (discovery analysis), following
Motzer et al (1999, 2002) and Heng et al (2009), baseline
factors were first individually evaluated for association with
OS using a univariate Cox proportional hazards model,
and subsequently evaluated using multivariate stepwise model
selection (forward selection at Pr0.1 to enter the model and
backward selection at Pr0.05 to stay in the model) (Table 2).
Each SNP was tested for association with OS using a multivariate
Cox model, assuming an additive genetic model, and adjusting
for the baseline factors identified by the stepwise model selection.
SNPs showing nominal significance (Pr0.05 without adjustment
for the number of SNPs tested) were considered for evaluation in
study 2.
Table 1. Demographic and clinical characteristics of patients in the three studies
Characteristics
Discovery, Study 1
(pazopanib) N¼241
Confirmation, Study 2
(pazopanib or sunitinib)
N¼729
Confirmation, Study 3
(sunitinib) N¼89
Age, median years (range) 60 (25–85) 61 (18–86) 65 (55–73)
Sex, n (%)
Male 170 (71) 552 (76) 61 (69)
Race, self-reported, n (%)
White 209 (87) 453 (62) 87 (98)
Non-white 32 (13) 276 (38) 2 (2)
Body mass index, median kgm 2 (range) 26 (14–46) 26 (15–55) NA
ECOG PS or Karnofsky score, n (%)
ECOG 0/KS 90–100 93 (39) 556 (76) 23 (28)
ECOG 1/KS 70–80 144 (60) 167 (23) 53 (64)
ECOG 2/KS p60/missinga 4 (2) 6 (1) 13 (14)
MSKCC risk score, n (%)
Favourable risk 94 (39) 211 (29) 27 (30)
Intermediate risk 130 (54) 420 (58) 44 (49)
Poor risk 2 (1) 73 (10) 2 (2)
Unknown 15 (6) 25 (3) 16 (18)
Time since initial diagnosis, n (%)
p1 year 74 (31) 400 (55) 47 (53)
41 year 139 (58) 329 (45) 42 (47)
Missing data 28 (12) 0 0
Prior nephrectomy status, n (%)
Yes 216 (90) 611 (84) 76 (85)
No 23 (10) 118 (16) 13 (15)
Missing data 2 (o1) 0 0
LDH, n (%)
p1  5ULN 215 (89) 673 (92) 82 (92)
41 5ULN 16 (7) 45 (6) 4 (4)
Missing data 10 (4) 11 (2) 3 (3)
Haemoglobin, n (%)
XLLN 129 (54) 445 (61) 55 (62)
oLLN 104 (43) 284 (39) 33 (37)
Missing data 8 (3) 0 1 (1)
Prior systemic treatment, n (%)
Treatment-naive 128 (53) 729 (100) 89 (100)
Cytokine-pretreated 105 (44) 0 0
Missing data 8 (3) 0 0
Neutrophil count, n (%)
pULN 194 (81) 643 (88) 0
4ULN 39 (16) 82 (11) 0
Missing data 8 (3) 4 (1) 89 (100)
Platelet count, n (%)
pULN 184 (76) 629 (86) 0
4ULN 49 (20) 98 (13) 0
Missing data 8 (3) 2 (o1) 89 (100)
PFS, median weeks (95% CI) 38 (28–52) 48 (38–49) 55 (33–77)
OS, median months (95% CI) 25 (22–28) 32 (28–36) 27 (17–37)
Tumour objective response, n (%)b 83 (37) 241 (33) 39 (49)c
Abbreviations: CI¼ confidence interval; ECOG PS¼Eastern Cooperative Oncology Group performance status; KS¼Karnofsky score; LDH¼ lactate dehydrogenase; LLN¼ lower limit of normal
range; MSKCC¼Memorial Sloan-Kettering Cancer Center; OS¼overall survival; PFS¼progression-free survival; ULN¼upper limit of normal range.
aOne patient had missing baseline ECOG PS. All patients with ECOG PS of 2 or missing were from study VEG107769, had been randomised to the placebo arm of VEG105192, and later
experienced disease progression while on treatment or during the follow-up period.
bObjective response represents complete response and partial response.
cNine had missing data, 49%¼ 39 complete þ partial responses/80 patients with data.
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In studies 2 and 3 (preplanned and post hoc confirmation
analyses, respectively), SNPs were tested for association with OS
using a multivariate Cox model, assuming an additive genetic model.
In study 2, analyses were adjusted for the same baseline covariates as
in study 1, plus ancestry principal components to adjust for
confounding by population structure (Price et al, 2006). In study 3,
analyses were adjusted for baseline Memorial Sloan-Kettering
Cancer Center (MSKCC) risk score and sex, as described previously
(Garcia-Donas et al, 2011). In parallel, SNPs nominally significantly
associated (Pr0.05) with either PFS or best response, as reported
previously (Xu et al, 2011), were also tested for association with
either PFS or best response in study 2. All analyses in study 2 were
conducted separately in pazopanib-treated and in sunitinib-treated
patients, and also in a combined analysis of all patients (with
additional covariate adjustment for treatment). Two-tailed P values
were reported, and patients with missing baseline covariates or
missing genotypes were excluded on a per-analysis basis.
Estimates of the natural-log hazard ratio (HR) from the
multivariate Cox model analyses for study 1, from the two
treatment arms of study 2 and from study 3, were combined using
inverse variance weighted meta-analysis, assuming fixed effects and
an additive genetic model. Heterogeneity of effects was assessed
using the I2 index of heterogeneity and by Cochran’s Q statistic.
For meta-analysis, a conservative significance threshold was
determined using Bonferroni correction for all discovery-only
and discovery-plus-confirmation analyses that could have been
conducted (27 SNPs  4 sequential analyses with increasing
cumulative sample sizes; threshold 0.05/27/4¼ 4.6 10 4). Sta-
tistical analyses were conducted using the R system (Free Software
Foundation, Boston, MA, USA), version 3.0.1.
RESULTS
We analyzed data from 1059 patients with advanced/metastatic
RCC: 241 pazopanib-treated patients in study 1 (discovery); 374
pazopanib-treated and 355 sunitinib-treated patients in study 2
(preplanned confirmation); 89 sunitinib-treated patients in
study 3 (post hoc confirmation). There was some heterogeneity
in demographic and baseline clinical characteristics across the
three datasets (Table 1). Similarly, there was a modest difference
between studies in OS (Table 1); this likely reflects differences in
baseline characteristics, as there was no significant difference in OS
between pazopanib- and sunitinib-treated patients within study 2
(Motzer et al, 2013).
Table 2 lists the baseline factors evaluated in study 1 (discovery).
Poor/intermediate MSKCC risk score, poor Eastern Cooperative
Oncology Group (ECOG) performance status, low haemoglobin,
high lactate dehydrogenase, high neutrophil count, increased
number of disease sites, shorter time since initial diagnosis, and
low body mass index were significantly associated with poor OS in
univariate analyses. Multivariate stepwise model selection identi-
fied ECOG status, neutrophil count, number of disease sites, time
since initial diagnosis, and body mass index as significantly
associated with OS (Pr0.05, Table 2). In analyses adjusted for
these five baseline factors, five of the 27 SNPs studied were
associated with OS at Pr0.05 in the discovery study 1 (Table 3).
Although no single association was significant after adjusting for
the 27 SNPs studied, the number of associations at Pr0.05 was
higher than expected by chance, and therefore we hypothesised
that some of these associations might be confirmed in a larger
independent dataset. Excluding the SNP where only two patients
carried the variant genotype, four SNPs were analyzed further.
We hypothesised that in patients with advanced RCC, genetic
effects on OS could be similar for angiogenesis inhibitors in the
same class (i.e., pazopanib and sunitinib). Therefore, for follow-up
of the discovery findings, we tested the four SNPs in both the
pazopanib and sunitinib arms of study 2. In analysis of all patients
in study 2, adjusted for treatment received, two IL8 SNPs were
associated with OS at Pr0.05 (rs1126647, Figure 1A; rs4073,
Supplementary Figure S1). Genotypes at these two IL8 SNPs were
strongly correlated with each other (study 1 r2¼ 0.79; Po0.0001),
Table 2. Effect of baseline factors on overall survival in pazopanib-treated patients in the univariate and multivariate cox
regression model in discovery study 1
Univariate Multivariatea
Factors HR (95% CI) P value HR (95% CI) P value
Age, increase/year 1.00 (0.98–1.01) 0.9 — —
Sex, female vs male 1.24 (0.88–1.73) 0.2 — —
Race, self-reported other vs white 0.92 (0.57–1.48) 0.7 — —
BMI, per kgm2 0.95 (0.91–0.98) 0.002 0.95 (0.92–0.99) 0.008
MSKCC risk score, intermediate/poor vs favourable 1.93 (1.37–2.73) 0.0002 — —
ECOG PS, 1 or 2 vs 0b 1.73 (1.25–2.42) 0.001 1.63 (1.12–2.38) 0.01
Haemoglobin, oLLN vs ZLLNb 1.53 (1.12–2.10) 0.008 — —
LDH, 41.5ULN vs r1.5ULNb 2.50 (1.41–4.42) 0.002 — —
Prior nephrectomy status, no vs yes 1.33 (0.81–2.21) 0.3 — —
Prior systemic treatment, treatment-naive vs cytokine-pretreated 1.24 (0.90–1.71) 0.2 — —
Number of disease sites, Z3 vs 1 or 2 1.24 (0.90–1.71) 0.003 1.56 (1.08–2.24) 0.02
Time from initial diagnosis to study entry, r1 year vs 41 yearb 1.81 (1.29–2.54) 0.0006 1.50 (1.05–2.15) 0.03
Neutrophil count, ULN vs rULN 1.82 (1.23–2.69) 0.003 1.66 (1.08–2.55) 0.02
Platelet count, 4ULN vs rULN 1.24 (0.86–1.80) 0.3 — —
Study, VEG105192 vs VEG107769 1.06 (0.72–1.56) 0.8 — —
Abbreviations: BMI¼body mass index; CI¼ confidence interval; ECOG PS¼Eastern Cooperative Oncology Group performance status; HR¼ hazard ratio; LDH¼ lactate dehydrogenase;
LLN¼ lower limit of normal range; MSKCC¼Memorial Sloan-Kettering Cancer Center; ULN¼upper limit of normal range.
aFor the multivariate model, HR and P values were shown for the final set of stepwise selected variables only; these variables were included as covariate(s) in the analysis of the effect of each
genetic marker.
bThese factors are also included in the calculation of the MSKCC risk score (Motzer et al, 1999, 2002).
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with rs1126647 (IL8 2767A4T) showing stronger association in
both study 1 and study 2. Therefore, we focused on this SNP for a
detailed description of the results. Given the inclusion of sunitinib-
treated patients in study 2 but not in study 1, and a lack of other
available genetic data for pazopanib-treated patients with advanced
RCC, we sought additional confirmation for the association of
rs1126647 in study 3.
In study 1 (pazopanib-treated, N¼ 241), rs1126647 was
significantly associated with OS (N¼ 186; 125 events; P¼ 0.007,
per allele HR¼ 1.45, 95% confidence interval (CI): 1.11–1.91; 18
patients had missing genotype data and 37 patients had missing
data for baseline factors) (Table 3, Figure 2). The effect size
estimate was similar when baseline factors were not adjusted for
(N¼ 223; 148 events; P¼ 0.003, per allele HR¼ 1.44, 95% CI:
1.13–1.83) (Figure 1A).
In study 2 (pazopanib- or sunitinib-treated, N¼ 729), rs1126647
was significantly associated with OS (N¼ 690; 287 events;
P¼ 0.018, HR¼ 1.23, 95% CI: 1.04–1.46, with adjustment for
treatment; 10 patients had missing genotype data and 29 patients
had missing data for baseline factors). The effect size estimate was
similar when baseline factors were not adjusted for (N¼ 719; 299
events; P¼ 0.014, HR¼ 1.24, 95% CI: 1.04–1.46) (Figure 1B).
The HRs for association between rs1126647 and OS were
not significantly different between pazopanib-treated patients
(N¼ 353; 146 events; P¼ 0.53, HR¼ 1.08, 95% CI: 0.84–1.40)
and sunitinib-treated patients (N¼ 337; 141 events; P¼ 0.008,
HR¼ 1.39, 95% CI: 1.09–1.77) in study 2 (Figure 2), with
overlapping CIs (Figure 3) and no significant genotype by
treatment interaction effect (P¼ 0.23). The lack of a nominally
significant association in pazopanib-treated patients in study 2
(P¼ 0.53) precludes straightforward interpretation of these results,
which is an issue we discuss further.
In study 3 (sunitinib-treated, N¼ 89), a significant association
between rs1126647 and OS, with similar effect size, was observed
(N¼ 88; 50 events; P¼ 0.034, HR¼ 1.62, 95% CI: 1.04–2.54; one
patient had missing genotype data) (Figures 1C and 2).
Meta-analysis of results from all three studies showed overall a
significant association between IL8 rs1126647 genotype and OS
(P¼ 8.8 10 5, HR¼ 1.32 per T allele, 95% CI: 1.15–1.52)
(Figure 2) that was significant after Bonferroni correction for all
discovery-only and discovery-plus-confirmation analyses that
could have been conducted using the available data (threshold
Pr4.6 10 4). There was no significant heterogeneity in genetic
effect size between studies (I2¼ 19%, Cochran’s Q¼ 3.73, 3 degrees
of freedom, P¼ 0.29).
Our previous pharmacogenetic analyses of pazopanib clinical
trials for RCC (using data from study 1 plus an additional clinical
trial that did not have OS data) suggested that three SNPs in the
Table 3. Association between genetic markers and overall survival in pazopanib-treated patients in discovery study 1
Gene Polymorphism rs Number
Minor Allele
Frequency, % P valuea HRa (95% CI)
CYP3A4 392A4G rs2740574 G 4.8 0.5 0.78 (0.39–1.55)
CYP3A5 6986A4G rs776746 A 11.8 0.98 1.00 (0.68–1.45)
NR1I2 25385C4T rs3814055 T 39.0 0.02 1.34 (1.04–1.73)
NR1I2 7635A4G rs6785049 G 40.6 0.7 0.96 (0.74–1.24)
NR1I2 10620C4T rs1054190 T 9.0 0.7 1.11 (0.71–1.73)
ABCB1 1236C4T rs1128503 T 43.2 0.054 1.25 (1.00–1.58)
ABCB1 2677G4T/A (A893S/T) rs2032582 T/A 45.4 0.3 1.14 (0.89–1.47)
ABCB1 3435C4T rs1045642 T 47.7 0.1 1.22 (0.94–1.58)
ABCG2 34G4A (V12M) rs2231137 A 9.0 0.5 0.85 (0.55–1.33)
ABCG2 421C4A (Q141K) rs2231142 A 13.5 0.7 1.06 (0.74–1.53)
ABCG2 869C4T (Q126X) rs72552713 T 0.4 0.03b 4.81 (1.15–20.18)
VEGFA  2578A4C rs699947 C 47.9 0.2 0.85 (0.66–1.09)
VEGFA 1498C4T rs833061 T 47.7 0.2 0.85 (0.66–1.09)
VEGFA 1154G4A rs1570360 A 33.5 0.09 1.25 (0.96–1.63)
VEGFA  634G4C rs2010963 C 27.8 0.2 0.83 (0.62–1.11)
VEGFA 936C4T rs3025039 T 15.3 0.4 1.15 (0.82–1.62)
VEGFR2 604T4C rs2071559 C 43.5 0.4 0.90 (0.70–1.14)
VEGFR2 889G4A (V297I) rs2305948 A 8.9 0.4 1.20 (0.77–1.86)
VEGFR2 1416A4T (Q472H) rs1870377 T 22.6 0.3 0.86 (0.64–1.16)
VEGFR3 1480A4G (T494A) rs307826 G 8.6 0.2 1.36 (0.85–2.19)
PDGFRa  573G4T rs1800812 T 21.7 0.3 0.86 (0.66–1.13)
IL8 2767A4T rs1126647 T 42.8 0.007 1.45 (1.11–1.91)
IL8 251T4A rs4073 A 49.8 0.02 1.36 (1.04–1.76)
FGF2 224C4T rs1449683 T 8.8 0.3 1.29 (0.78–2.12)
FGFR2 IVS2 þ 906C4T rs2981582 T 38.8 0.008 1.40 (1.09–1.81)
HIF1a 1772C4T (P582S) rs11549465 T 10.3 0.6 0.88 (0.58–1.34)
HIF1a 1790G4A (A588T) rs11549467 A 3.2 0.6 0.84 (0.42–1.65)
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio.
aThe HR and P values were from additive genetic models. The P values were nominal values without adjustment for the number of SNPs tested; HR values represent the per variant allele allelic HR.
bAlthough the ABCG2 rs72552713 was nominally significantly associated with overall survival, this association was driven by the only two patients with the variant CT genotype, and thus was not
further discussed in this manuscript.
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IL8 and HIF1A genes may be associated with PFS, and that five
SNPs in the HIF1A, NR1I2, and VEGFA genes may be associated
with best response (Xu et al, 2011). None of these SNPs showed
nominally significant association (at Pr0.05) with either PFS or
best response in follow-up analyses in the subset of pazopanib-
treated patients from study 2, but IL8 SNPs were weakly associated
with PFS in sunitinib-treated patients.
DISCUSSION
Several antiangiogenesis agents are available for the treatment of
advanced/metastatic RCC. However, few reliable predictors for
treatment outcomes are available. The only externally validated
models are the MSKCC or the International Metastatic Renal-Cell
Carcinoma Database Consortium (IMDC) criteria that include
baseline clinical factors to separate patients into risk categories
with different prognoses (Motzer et al, 2002; Heng et al, 2013).
Therefore, there is a growing interest in the field to explore pre-
treatment demographic and clinical factors, serum/tissue biomar-
kers, and germline genetic markers that are potentially associated
with efficacy endpoints. Here, using data from 1059 patients in
three independent datasets, we report that rs1126647 in IL8 is
associated with OS in pazopanib- or sunitinib-treated patients with
advanced RCC. Although the variant IL8 genotype (TT) was
associated with shorter OS than other genotypes, all genotype
subgroups had survival benefit from treatment with pazopanib or
sunitinib. For example, the median OS was 21.4–23.7 months for
patients with the variant TT genotype and 27.8–35.5 months for
the other genotypes in COMPARZ (Figure 3), all of which were
substantially improved compared with historical survival data in
advanced RCC when cytokines were the mainstay treatment
(median survival 13 months) (Motzer et al, 2000). As the
magnitudes of OS benefit vary depending on IL8 genotypes,
alternative sequencing or combination treatment strategies that are
based on genotyping could be explored in the future as new
therapies become available. Furthermore, the IL8 genotype data
could be incorporated into a prognostic model such as the existing
IMDC model to improve the predictions of patients’ clinical
outcomes (Heng et al, 2013).
Progression-free survival has been used as a primary endpoint
in some oncology clinical trials and has been considered an
acceptable surrogate for OS in some settings (Shea et al, 2013; Bria
et al, 2015). We were able to demonstrate association of IL8
rs1126647 with OS but not with PFS. However, surrogacy with
respect to the effect of a targeted therapy need not imply surrogacy
with respect to effects of genetic differences, which may have
distinct mechanism(s) of action (Fleming and DeMets, 1996). This
raises the possibility that IL8 variants may be associated with OS
irrespective of treatment.
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Figure 1. Overall survival Kaplan–Meier curves for patients by each IL8 2767A4T (rs1126647) genotype. (A) Pazopanib-treated patients in
discovery study 1 (from NCT00334282 and NCT00387764): of the 241 patients, 223 had IL8 genotype data and were included in this plot
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Figure 2. Forest plot of meta-analysis association results between IL8 rs1126647 polymorphism and OS across three independent studies (with
confirmation study 2 split into pazopanib- and sunitinib-treated subgroups). The HR was per variant T allele compared with reference A allele using
an additive genetic model.
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As with many cancer therapies, the benefit of antiangiogenic
therapy is often transient in the metastatic disease setting, and
there has been an ongoing search to identify mechanisms of
resistance. Although clinical examples of clearly established
mechanisms of resistance to angiogenesis inhibitors remain
limited, findings from cell culture and murine model studies have
revealed that activation of alternate or redundant signalling
pathways may represent one such mechanism (Mizukami et al,
2005; Huang et al, 2010). The IL8 protein possesses mitogenic and
angiogenic properties (Koch et al, 1992), and IL8-mediated
angiogenesis was identified as a key compensatory mechanism of
resistance to sunitinib in murine models of RCC (Huang et al,
2010). The IL8 variant alleles evaluated in this study have been
previously shown to be associated with increased gene expression
(Hacking et al, 2004). Overexpression of IL8 is correlated with
tumour stage, disease progression, and recurrence in various
cancers (Yuan et al, 2005), as well as worse prognosis in localised
RCC (Rini et al, 2010). In patients receiving pazopanib or
sunitinib, high baseline serum IL8 levels were associated with
shorter PFS and/or OS, suggesting that serum IL8 concentrations
may be a prognostic or predictive factor for metastatic RCC (Liu
et al, 2011; Tran et al, 2012; Harmon et al, 2014). One could
therefore speculate that patients carrying the high-expression IL8
variants may have more aggressive tumours and thus reduced
survival vs those carrying the low-expression genotypes. It may be
reasonable to consider IL8 blockade as a potential therapeutic
target in future drug development for this patient subset.
Pharmacogenetic studies are often hampered by small sample
sizes and limited availability of validation studies with eligibility
criteria and treatment regimen similar to the discovery study.
Strengths of the present study include a hypothesis-driven
approach in a relatively large sample size study, the availability
of one discovery and two confirmatory datasets, and detailed data
on patient baseline characteristics. The prospective collection of
germline DNA samples during pazopanib clinical trials enabled the
evaluation of the effects of genetic markers on clinical response.
Our evidence for association between OS and IL8 rs1126647 in
pazopanib- and sunitinib-treated patients with RCC is based on a
combined analysis of all data available for this study. Clearly, these
data were accumulated in stages, and the inclusion of study 3 data
in our analysis was post hoc. Nonetheless, the strength of
association based on all available data (P¼ 8.8 10 5) remains
significant after a conservative multiple testing correction that
accounts for the number of stages of data accumulation and also
for the total number of SNPs that could have been followed
through these stages (threshold Pr4.6 10 4). The evidence for
association of IL8 rs1126647 in patients treated with either
pazopanib or sunitinib is supported by substantially overlapping
95% CIs from treatment-specific meta-analyses (pazopanib 95%
CI: 1.03–1.50, sunitinib 95% CI: 1.16–1.78) (Figure 2). However,
the association between OS and IL8 rs1126647 in patients with
RCC requires bona fide prospective validation in further
independent studies.
In conclusion, data from the present study suggest that variant
alleles (associated with high expression) in the IL8 gene are
associated with poorer survival outcome in patients with RCC who
have received pazopanib or sunitinib. These findings provide
additional scientific insight in the prognosis of advanced RCC after
antiangiogenesis therapy, and may advance our thinking in
developing new therapies.
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